Utilizing Quality-Adjusted Life Years in Ovarian Cancer Treatment Decision-Making

2020 ◽  
Keyword(s):  
Ovarian Cancer ◽  
Decision Making ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Quality Adjusted Life Years ◽  
Treatment Decision Making ◽  
Life Years ◽  
Quality Adjusted Life

The Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients

2022 ◽  
Author(s):  
Larissa Elisabeth Hillebrand ◽  
Ulrike Söling ◽  
Norbert Marschner
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Metastatic Breast Cancer ◽  
Cancer Treatment ◽  
Patient Reported Outcomes ◽  
Metastatic Breast ◽  
Treatment Decision ◽  
Breast Cancer Patients ◽  
Treatment Decision Making ◽  
Patient Reported

Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient´s quality of life (QoL), delaying disease progression, and prolonging survival. Curing the disease is not possible in the palliative setting. To better understand metastatic breast cancer patients, their symptoms and wishes, which are important for treatment-decision making and outcome, patient-reported outcomes (PROs) are of great importance, giving an impression of what really matters to and concerns a patient. Summary: Many advances have been made to implicate PROs in clinical trials, non-interventional studies, registries, and clinical routine care of metastatic breast cancer. For example, large phase III trials like PALOMA-3 (NCT01942135), MONALEESA-7 (NCT02278120), HER2CLIMB (NCT02614794), and KEYNOTE-119 (NCT02555657) trials implemented PROs in their trial design to assess the QoL of their trial patients. Also, non-interventional studies on metastatic breast cancer, like e.g., the NABUCCO study (IOM-02240), and prospective non-interventional, multicenter registries e.g., the tumor registry breast cancer (NCT01351584) or the breast cancer registry platform OPAL (NCT03417115), have implemented PROs to assess QoL during the anti-cancer treatment periods of the patients. Key Message: Using PROs in metastatic breast cancer can support shared treatment-decision making and management of symptoms, eventually leading to an improvement in QoL. Progressively, regulatory authorities take PROs into consideration for the approval of new drugs. Hence, the implication of PROs in cancer treatment, and especially in MBC, is of significant value.

scholarly journals Perceived importance of affective forecasting in cancer treatment decision making

2020 ◽  
Vol 38 (6) ◽  
pp. 687-701
Author(s):  
Laura M. Perry ◽  
Michael Hoerger ◽  
Brittany D. Korotkin ◽  
Paul R. Duberstein
Keyword(s):  
Decision Making ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Affective Forecasting ◽  
Treatment Decision Making ◽  
Perceived Importance

scholarly journals The TRIO Framework: Conceptual insights into family caregiver involvement and influence throughout cancer treatment decision-making

2017 ◽  
Vol 100 (11) ◽  
pp. 2035-2046 ◽  
Author(s):  
Rebekah Laidsaar-Powell ◽  
Phyllis Butow ◽  
Cathy Charles ◽  
Amiram Gafni ◽  
Vikki Entwistle ◽  
...  
Keyword(s):  
Decision Making ◽  
Cancer Treatment ◽  
Family Caregiver ◽  
Treatment Decision ◽  
Treatment Decision Making ◽  
Caregiver Involvement

Medical Costs and Outcomes for Australian Women With Ovarian Cancer: A Patient-Level Analysis Over 2.5 Years

2010 ◽  
Vol 20 (5) ◽  
pp. 757-765 ◽  
Author(s):  
Louisa G. Gordon ◽  
Paul A. Scuffham ◽  
Vanessa L. Beesley ◽  
Adèle C. Green ◽  
Anna DeFazio ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adverse Effects ◽  
Medical Costs ◽  
Stage I ◽  
Disease Stage ◽  
Quality Adjusted Life Years ◽  
First Line ◽  
Direct Medical Costs ◽  
Life Years ◽  
Quality Adjusted Life

Objective:As treatment costs for gynecological cancer escalate, real-world data on use of resources and costs becomes increasingly important. This study investigated medical costs, quality of life, and survival end points for women with ovarian cancer in Australia.Methods:Women with primary epithelial ovarian cancer referred for chemotherapy (n = 85) were recruited through 7 hospitals in Australia. Overall survival, progression-free interval, and quality-adjusted life years were assessed by stage using the Cox proportional hazards models. Direct medical costs, including those for surgeries, hospitalizations, supportive care, chemotherapy, and adverse effects (while on chemotherapy), were calculated over 2.5 years and assessed by nonparametric bootstrapping.Results:Quality-adjusted life years decreased with increased disease stage at diagnosis and ranged from 2.3 for women with stage I or II disease to 1.3 for those with stage IV disease. A total of AU $4.1 million (2008) were spent on direct medical costs for 85 women over approximately 2.5 years. Medical costs were significantly higher for women with stage III or IV disease compared with that for women with stage I or II disease ($50,945 vs $31,958,P< 0.01) and/or women who experienced surgical complications and/or adverse effects requiring hospitalization while on chemotherapy ($57,821 vs $34,781,P< 0.01). Costs after first-line chemotherapy were significantly higher for women with advanced disease (mean, $20,744) compared with those for women with early disease (mean, $5525;P< 0.01).Conclusions:Whereas for women with early-stage ovarian cancer, costs are concentrated in the period of primary treatment, cumulated costs are especially high for women with recurrent disease rising rapidly after first-line therapy.

Abstract A047: An ethnographic study of African American men's prostate cancer treatment decision-making

2020 ◽  
Author(s):  
Nynikka R. Palmer ◽  
Richard L. Street ◽  
Dean Schillinger ◽  
Janet K. Shim ◽  
Sarah D. Blaschko ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
African American ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Ethnographic Study ◽  
Prostate Cancer Treatment ◽  
Treatment Decision Making
Sign in / Sign up

Export Citation Format

Share Document